Literature DB >> 24878455

A systematic review and meta-analysis of the clinicopathologic characteristics of cystic versus solid pancreatic neuroendocrine neoplasms.

Ye-Xin Koh1, Aik-Yong Chok1, Hui-Li Zheng2, Chuen-Seng Tan2, Brian K P Goh3.   

Abstract

INTRODUCTION: Cystic pancreatic neuroendocrine neoplasms (PNENs) are rare neoplasms, and presently, it is uncertain whether their behavior is similar or distinct from their solid counterparts. This study aimed to review systematically the present literature to compare the clinicopathologic characteristics of cystic PNENs versus their solid counterparts to determine whether cystic PNENs are likely to be a distinct entity from solid PNENs.
METHODS: Comparative studies of solid versus cystic PNENs studies were reviewed. Cystic and solid PNENs were compared on the basis of several clinicopathologic characteristics.
RESULTS: Seven nonrandomized case control studies compared 152 cystic versus 915 solid PNENs. Pooled analysis demonstrated that the likelihood of PNENs to be located in the head/uncinate of the pancreas was lower for cystic than solid neoplasms (27.7% vs 45.5%, odds ratio [OR] 0.452, 95% confidence interval [95% CI] 0.304-0.673, P < .001). Cystic PNENs were less likely to be functional (14% vs 24.4%, OR 0.405, 95% CI 0.221-0.742, P = .003) and were more likely to be benign/uncertain rather than malignant compared with solid PNENs (90.3% vs 65.9%, OR 3.151, 95% CI 1.297-7.652, P = .011). Cystic PNENs were more likely to have a mitotic count <2 per 10 hpf and a Ki67 index <2% (93.3% vs 72.7%, OR 4.897, 95% CI 2.139-11.209, P < .001 and 82.4% vs 54.1%, OR 4.079, 95% CI 2.177-7.641, P < .001), respectively. Cystic neoplasms were also less likely to have regional lymph node metastases than solid neoplasms (11.2% vs 28.9%, OR 0.387, 95% CI 0.219-0.685, P = .001).In this meta-analysis, there was no difference in the 5-year overall survival and 5-year disease-free survival between cystic vs solid PNENs (92.0% vs 86.8%, P .214) and (98.1% vs 83.9%, P = .185).
CONCLUSION: These findings suggest that cystic PNENs tend to be biologically less aggressive compared with their solid counterparts; more data, however, with respect to molecular analysis are required to establish whether cystic and solid PNENs were distinct pathologic entities.
Copyright © 2014 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24878455     DOI: 10.1016/j.surg.2014.03.026

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  16 in total

1.  Pancreatic cystic lesions: risk stratification and management based on recent guidelines.

Authors:  Benjamin M Stutchfield; Manu Nayar; Ian D Penman
Journal:  Frontline Gastroenterol       Date:  2019-02-18

2.  A case of pancreatic neuroendocrine tumor with multiple cystic components of various sizes.

Authors:  Makiko Yasumoto; Yoshinobu Okabe; Gen Sugiyama; Yoshiki Naito; Masamichi Nakayama; Toru Hisaka; Hiroto Ishikawa; Hiroyuki Horiuchi; Yukiko Kunou; Tomoyuki Ushijima; Yusuke Ishida; Osamu Tsuruta; Takuji Torimura
Journal:  Clin J Gastroenterol       Date:  2017-12-21

3.  Neuroendocrine neoplasm of pancreas with cystic degeneration mimicking mucinous cystic neoplasm.

Authors:  Uayporn Kaosombatwattana; Yoshiki Hirooka; Hiroki Kawashima; Eizaburo Ohno; Takuya Ishikawa; Hiroki Suhara; Hidemi Goto
Journal:  Clin J Gastroenterol       Date:  2018-03-13

Review 4.  Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-17       Impact factor: 4.512

5.  Contrast-enhanced harmonic endoscopic ultrasound using time-intensity curve analysis predicts pathological grade of pancreatic neuroendocrine neoplasm.

Authors:  Saimon Takada; Hironari Kato; Yosuke Saragai; Shinichiro Muro; Daisuke Uchida; Takeshi Tomoda; Kazuyuki Matsumoto; Shigeru Horiguchi; Noriyuki Tanaka; Hiroyuki Okada
Journal:  J Med Ultrason (2001)       Date:  2019-08-03       Impact factor: 1.314

6.  c-Met affects gemcitabine resistance during carcinogenesis in a mouse model of pancreatic cancer.

Authors:  Kozo Noguchi; Masamitsu Konno; Hidetoshi Eguchi; Koichi Kawamoto; Ryouta Mukai; Naohiro Nishida; Jun Koseki; Hiroshi Wada; Hirofumi Akita; Taroh Satoh; Shigeru Marubashi; Hiroaki Nagano; Yuichiro Doki; Masaki Mori; Hideshi Ishii
Journal:  Oncol Lett       Date:  2018-05-24       Impact factor: 2.967

7.  Precancerous Lesions and Carcinoma of the Pancreas.

Authors:  Markus W Büchler; Irene Esposito; Lars Grenacher; Thilo Hackert; Julia Mayerle
Journal:  Viszeralmedizin       Date:  2015-02-03

Review 8.  Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer.

Authors:  Bo Tang; Yang Li; Guangying Qi; Shengguang Yuan; Zhenran Wang; Shuiping Yu; Bo Li; Songqing He
Journal:  Sci Rep       Date:  2015-09-04       Impact factor: 4.379

Review 9.  Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau disease.

Authors:  Xavier M Keutgen; Pascal Hammel; Peter L Choyke; Steven K Libutti; Eric Jonasch; Electron Kebebew
Journal:  Nat Rev Clin Oncol       Date:  2016-03-31       Impact factor: 66.675

10.  Morphological differentiation and follow-up of pancreatic cystic neoplasms using endoscopic ultrasound.

Authors:  Susumu Hijioka; Kazuo Hara; Nobumasa Mizuno; Hiroshi Imaoka; Vikram Bhatia; Kenji Yamao
Journal:  Endosc Ultrasound       Date:  2015 Oct-Dec       Impact factor: 5.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.